Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed plus Tarceva in EGFR-overexpressed metastatic colorectal cancer
NCT03086538Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- May 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and erlotinib in colorectal cancer (CRC), sponsored by Samsung Medical Center. Primary endpoint: Overall Response Rate at 6 months. Started May 2017; status: completed.
02
Drugs
pemetrexederlotinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03086538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03086538.